Patent Granted
June 29 2009 - 2:00AM
UK Regulatory
TIDMLPX
RNS Number : 6384U
Lipoxen PLC
29 June 2009
+--------------------------------------+--------------------------------------+
| For immediate release | 29 June 2009 |
+--------------------------------------+--------------------------------------+
Lipoxen plc
('Lipoxen' or 'the Company')
Lipoxen's Co-Delivery DNA Vaccine Patent Granted in EU and US
Improved immune response using ImuXen liposomal technology
Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the
development of high-value differentiated biologicals, vaccines and siRNA
delivery, announces today that it has been granted a new Co-Delivery DNA Vaccine
Patent in EU and US for its ImuXen liposomal technology. The new patent claims
that Lipoxen's ImuXen technology can induce an even further enhanced immune
response for vaccine delivery when the DNA and antigen components are combined
together into the liposomal delivery system. This new patent is a sequel to
Lipoxen's existing patent surrounding ImuXen where an improved immune response
was demonstrated previously when DNA alone was entrapped in the liposome
technology.
ImuXen is based on Lipoxen's proprietary techniques that allow the liposomal
entrapment of vaccine materials, resulting in enhanced immune responses while
reducing the side effects, a feature of traditional vaccines. Co-Delivery
provides a gentle but powerful stimulus to the immune response by combining DNA
and protein vaccine materials in liposomes. Co-Delivery emulates the effect of a
live virus vaccine by delivering its materials (DNA and protein) to the same
cells in the immune system potentially resulting in single shot vaccines, while
avoiding the risk of infection inherent in live virus vaccines. It also avoids
the use of aluminium, a toxic element widely used in killed or subunit vaccines.
Lipoxen's Co-Delivery technology has been adopted in collaborative projects with
the world's leading AIDS vaccine organization, International AIDS Vaccine
Initiative (IAVI), and PATH's Malaria Vaccine Initiative, involving the National
Institutes of Health. Co-Delivery has the potential to provide safer and more
effective vaccines against a range of serious diseases that continue to afflict
man.
Commenting on the patent grant, M. Scott Maguire, CEO of Lipoxen, said: "The new
patent grant on this novel vaccine system is another significant milestone for
Lipoxen and further supports our drive to become a leading innovator in
vaccines. We have several collaborations in place with some of the world's
leading vaccine companies and further technology evaluation projects underway.
We expect this new patent will strengthen our capability to collaborate with
partners and we look forward to announcing progress on this front in due
course."
- Ends -
For further information please contact:
+-------------------------------------------------+-------------------------+
| Lipoxen plc | +44 (0)20 7389 5015 |
+-------------------------------------------------+-------------------------+
| M. Scott Maguire, Chief Executive Officer | |
+-------------------------------------------------+-------------------------+
| | |
+-------------------------------------------------+-------------------------+
| Singer Capital Markets (nominated adviser) | +44 (0)20 3205 7500 |
+-------------------------------------------------+-------------------------+
| Jeff Keating / Claes Spång | |
+-------------------------------------------------+-------------------------+
| | |
+-------------------------------------------------+-------------------------+
| Noble & Company | +44 (0) 20 7763 2200 |
+-------------------------------------------------+-------------------------+
| John Llewellyn-Lloyd / Sam Reynolds | |
+-------------------------------------------------+-------------------------+
| | |
+-------------------------------------------------+-------------------------+
| Buchanan Communications | +44 (0)20 7466 5000 |
+-------------------------------------------------+-------------------------+
| Mary-Jane Elliott, Lisa Baderoon, Rebecca Skye | |
| Dietrich, Catherine Breen | |
+-------------------------------------------------+-------------------------+
Notes for Editors
About Lipoxen
Lipoxen plc is a biopharmaceutical company focused on the development of new and
improved biologic drugs and vaccines. Lipoxen has three proprietary patented
technology platforms:
1) PolyXen - for extending the efficacy and half life of biologic drugs
2) ImuXen - for creating new vaccines and improving existing vaccines
3) SiRNAblate - for the delivery of siRNA
Lipoxen's technology is designed to improve the efficacy, safety, stability,
biological half-life and immunologic characteristics of its products.
Lipoxen has multiple drug and vaccine programmes in development. Two products
are in clinical development, SuliXen, a long acting insulin and ErepoXen, a
long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes
vaccines against HIV, influenza and malaria and Factor VIII through an exclusive
license with Baxter, the global healthcare company.
The Company has a low-risk business model and out-licenses its proprietary
technologies to biopharmaceutical companies that have strong manufacturing and
marketing capabilities. Lipoxen currently has commercial agreements with some of
the world's leading biotechnology and pharmaceutical companies including Baxter,
Schering-Plough, Sanofi-Aventis, the Serum Institute of India Limited,
Genentech, Amgen and Genzyme. Furthermore, Baxter led the GBP2.9 million
fundraising that the Company announced in May 2009, with a US$1 million
investment.
Lipoxen, which was founded in 1997, now trades on the AIM Market of the London
Stock Exchange under the ticker symbol LPX. More information can be found at the
Company's website: www.lipoxen.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLVLLLKQBFBBF
Lipoxen (LSE:LPX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lipoxen (LSE:LPX)
Historical Stock Chart
From Jul 2023 to Jul 2024
